New Launch22 Jan 2026, 09:56 am
Zydus Lifesciences Launches World's First Nivolumab Biosimilar 'Tishtha' in India
AI Summary
Zydus Lifesciences Ltd, an innovation-led life-sciences company, has launched the world’s first biosimilar of Nivolumab in India under the brand name Tishtha™. The immunotherapy reduces treatment burden by making it accessible at approximately 1/4th cost of the reference drug. The treatment is likely to benefit more than 5 lakh patients in India. Developed and manufactured in India, Tishtha™ ensures long-term dependability for patients throughout their treatment journey.
Key Highlights
- Zydus launches the world’s first biosimilar of Nivolumab, ‘Tishtha™”, in India to treat multiple cancers
- The immunotherapy reduces treatment burden by making it accessible at approximately 1/4th cost of the reference drug
- Tishtha™ will be available in 100 mg and 40 mg dosages priced at 228,950 and 213,950 respectively
- Developed and manufactured in India, Tishtha™ ensures long-term dependability for patients throughout their treatment journey
- The launch of Tishtha™ is expected to benefit more than 5 lakh patients in India